EFEK KARDIOTOKSIK OBAT KEMOTERAPI DOXORUBICIN

Main Article Content

Abed Nego Okthara Sebayang

Abstract

Introduction: Doxorubicin is an anthracycline class antibiotic that is widely used for the
treatment of various types of cancers such as acute leukemia, breast cancer, bone and
ovarian cancer. This compound was isolated from streptomyces peucetius var caesius and
was used extensively in the treatment of cancer. But doxorubicin has a fairly dangerous
cardiotoxic effect. Myocardial dysfunction by the use of doxorubicin can occur due to the
formation of free radicals that are harmful to the heart.
Discussion: Doxorubicin is the most widely used anthracycline drug in cancer treatment.
Side effects that often arise from the use of doxorubicin are cardiotoxic. Myocardial
dysfunction caused by doxorubicin may be caused by free radicals formed, impaired
adrenergic function, formation of lipid peroxides, impaired transport of Ca in the
sarcollemma, release of TNFα and interleukin-2 and cytokines free of tumor tissue. The
mechanism of oxidative stress is the mechanism that most often results in damage to the
heart.
Conclusion: Doxorubicin is an anthracycline drug that is widely used in cancer treatment.
Doxorubicin has quite dangerous side effects, namely cardiotoxic. Cardiotoxics can cause
heart failure. For this reason, a clinical approach must be taken in using doxorubicin to
monitor the toxic effects.

Article Details

How to Cite
Sebayang, A. (2021). EFEK KARDIOTOKSIK OBAT KEMOTERAPI DOXORUBICIN. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 7(1), 1-5. https://doi.org/10.53366/jimki.v7i1.387
Section
Advertorial

References

1. Minotti G, Menna P, Salvatorelli E,
Cairo G, Gianni L. Antracyclins:
Moleculer Advances and
pharmacologic Developments in
Antitumor Activity and Cardiotoxicity.
Pharmacol Rev; 2004.185-228
2. Bruton L, Lazo JS, Parker KL.
Goodman & Gilman’s The
Pharmacological Basis of
Therapeutics. Edisi ke 11. 2005.
McGrawHill.
3. Childs AC, Phaneuf SL, Dirks AJ,
Philips T, Leeuwenburgh.
Doxorubicin Treatment In Vivo
Causes Cythocrome c Release and
Cardiomyocyte Apaptosis, As Well As
Increased Mithocondrial Efficiency,
Superoxide Dismutase Activity, and
Bcl-2. Cancer Research. 2002. 4592-
4598.
4. Han X, Pan J, Ren D, Cheng Y, Fan
P, Lou H. Naringenin-7-O-glucoside
Protects Againts Doxorubicin-Induced
Toxicity in H9C2 Cardiomyocytes by
Induction of Endogenous Antioxidant
Enzymes, Food and Chemical
Toxicology. 2008. 3140-3146.
5. Kremer LCM, van Dalen EC, Offringa
M, OttenkampJ, Voute
PA.Anthracycline Induced Clinical
Heart Failure In a Cohort of 607
Children: Long Term Follow Up Study.
J Clin Oncol; 2001.191-196.
6. Khan AC, Srinivasan S, Czuczman
MS. Prevention and management of cardiotoxicity from antineoplastic
therapy. J Support Oncol; 2004.251-
266.
7. Rilantono LI. Penyakit Kardiovaskular
(PKV) 5 rahasia. Edisi ke1. Jakarta:
Fakultas Kedokteran universitas
Indonesia; 2015. 381-400p.